

**European Haemophilia Consortium**

***World Haemophilia Day***

**Wednesday 19 April 2017**

**European Directorate for Quality of Medicines and Healthcare (EDQM)  
Strasbourg, France**

**AGENDA**

---

10.00 – 11.00	<b>Registration</b>
11.00 – 11.15	<b>Welcome and introduction</b> <i>Dr Susanne Keitel, EDQM</i> <i>Mr Brian O'Mahony, EHC</i>
11.15 – 11.45	<b>Overview of the Wildbad Kruth consensus recommendations</b> <i>Prof Wolfgang Schramm, University of Munich</i> <i>Dr Marie-Emmanuelle Behr-Gross, EDQM</i> <i>Mr Brian O'Mahony, EHC</i>
11.45 – 12.00	<b>EHC PARTNERS Project</b>
12.00 – 13.00	<b>Importance of the Wildbad Kreuth consensus recommendations – experiences from patients and clinicians</b> <i>Moderator: Prof Paul Giangrande, EHC Medical Advisory Group</i> <i>Discussions:</i> Importance of a formal designation for treatment centres – EUHANET so far and next steps <i>Mr Brian O'Mahony, EHC</i> Importance of minimum factor concentrates levels <i>Prof Margit Serban and Mr Daniel Andrei, EHC Romanian NMO</i> Ageing and haemophilia <i>Mr Cees Smit, EGAN</i> Importance of access to HCV treatment <i>Mr Ger O'Reilly, EHC Irish NMO</i> <i>Discussions</i>

---



---

13.00 – 14.00 **Lunch**

---

14.00 – 15.15 **Importance of the Wildbad Kreuth consensus recommendations – experiences from patients and clinicians**

*Moderator: Prof Paul Giangrande, EHC Medical Advisory Group*

Tenders – Ukraine and UNDP collaboration  
*Mr Zafar Yuldoshev, UNDP Ukraine (via Webex)*

Genotyping and carriers  
*Ms Naja Skouw-Rasmussen, EHC Steering Committee*

Inhibitors, EIN and inhibitor treatment guidelines  
*Prof Cedric Hermans, EAHAD*  
*Mr Mirko Jokic, EHC European Inhibitor Network*

Outcome data  
*Dr Radoslaw Kaczmarek, EHC Steering Committee*

---

15.15 – 15.45 **Why are the Wildbad Kreuth consensus recommendations important? Practical experience**

---

15.45 – 16.00 **Discussions and conclusions**

---